603 results on '"Gillespie, G. Yancey"'
Search Results
252. Inflammatory Cells in Solid Murine Neoplasms
- Author
-
Gillespie, G. Yancey, primary, Hansen, Christopher B., additional, Hoskins, Ronald G., additional, and Russell, Stephen W., additional
- Published
- 1977
- Full Text
- View/download PDF
253. Intracarotid cisplatin chemotherapy for recurrent gliomas
- Author
-
Mahaley, M. Stephen, primary, Hipp, Stephen W., additional, Dropcho, Edward J., additional, Bertsch, Linda, additional, Cush, Sharon, additional, Tirey, Tammy, additional, and Gillespie, G. Yancey, additional
- Published
- 1989
- Full Text
- View/download PDF
254. Macrophage-Derived Growth Factor for Fibroblasts and Interleukin-1 Are Distinct Entities
- Author
-
Estes, John E., primary, Pledger, W.J., additional, and Gillespie, G. Yancey, additional
- Published
- 1984
- Full Text
- View/download PDF
255. Systemic gamma-interferon therapy for recurrent gliomas
- Author
-
Mahaley, M. Stephen, primary, Bertsch, Linda, additional, Cush, Sharon, additional, and Gillespie, G. Yancey, additional
- Published
- 1988
- Full Text
- View/download PDF
256. Receptor Sites for Antigen-Antibody Complexes on Cells Derived from Solid Tumors: Detection by Means of Antibody Sensitized Sheep Erythrocytes Labeled with Technetium-99m
- Author
-
Wood, Gary W., primary, Gillespie, G. Yancey, additional, and Barth, Rolf F., additional
- Published
- 1975
- Full Text
- View/download PDF
257. Laser photochemotherapy of rhodamine-123 sensitized human glioma cells in vitro
- Author
-
Powers, Stephen K., primary, Pribil, Stefan, additional, Gillespie, G. Yancey, additional, and Watkins, Pamela J., additional
- Published
- 1986
- Full Text
- View/download PDF
258. The golden age of mononuclear phagocytes
- Author
-
Gillespie, G. Yancey, primary
- Published
- 1982
- Full Text
- View/download PDF
259. A controlled study of efficacy of interstitial or external irradiation in a virus-induced brain-tumor model in rats
- Author
-
El-Hennawi, Yehia, primary, Gillespie, G. Yancey, additional, Mahaley, M. Stephen, additional, Varia, Mahesh A., additional, Bigner, Darell D., additional, and Stanton, Constance, additional
- Published
- 1989
- Full Text
- View/download PDF
260. Isolation of T-Lymphocytes From Disaggregated Tumors, With High Purity and Good Percentage Recovery: Brief Communication23
- Author
-
Hansen, Christopher B., primary, Gillespie, G. Yancey, additional, and Russell, Stephen W., additional
- Published
- 1977
- Full Text
- View/download PDF
261. Systemic beta-interferon therapy for recurrent gliomas: a brief report
- Author
-
Mahaley, M. Stephen, primary, Dropcho, Edward J., additional, Bertsch, Linda, additional, Tirey, Tammy, additional, and Gillespie, G. Yancey, additional
- Published
- 1989
- Full Text
- View/download PDF
262. Inflammatory Cells in Solid Murine Neoplasms
- Author
-
Russell, Stephen W., primary, Gillespie, G. Yancey, additional, and McIntosh, Ann Tozier, additional
- Published
- 1977
- Full Text
- View/download PDF
263. Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.
- Author
-
Friedman, Gregory K., Bernstock, Joshua D., Chen, Dongquan, Nan, Li, Moore, Blake P., Kelly, Virginia M., Youngblood, Samantha L., Langford, Catherine P., Han, Xiaosi, Ring, Eric K., Beierle, Elizabeth A., Gillespie, G. Yancey, and Markert, James M.
- Abstract
Pediatric high-grade brain tumors and adult glioblastoma are associated with significant morbidity and mortality. Oncolytic herpes simplex virus-1 (oHSV) is a promising approach to target brain tumors; oHSV G207 and M032 (encodes human interleukin-12) are currently in phase I clinical trials in children with malignant supratentorial brain tumors and adults with glioblastoma, respectively. We sought to compare the sensitivity of patient-derived pediatric malignant brain tumor and adult glioblastoma xenografts to these clinically-relevant oHSV. In so doing we found that pediatric brain tumors were more sensitive to the viruses and expressed significantly more nectin-1 (CD111) than adult glioblastoma. Pediatric embryonal and glial tumors were 74-fold and 14-fold more sensitive to M002 and 16-fold and 6-fold more sensitive to G207 than adult glioblastoma, respectively. Of note, pediatric embryonal tumors were more sensitive than glial tumors. Differences in sensitivity may be due in part to nectin-1 expression, which predicted responses to the viruses. Treatment with oHSV resulted in prolonged survival in both pediatric and adult intracranial patient-dervied tumor xenograft models. Our results suggest that pediatric brain tumors are ideal targets for oHSV and that brain tumor expression of nectin-1 may be a useful biomarker to predict patient response to oHSV. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
264. Tamoxifen Induces Cytotoxic Autophagy in Glioblastoma
- Author
-
Graham, Christopher D., Kaza, Niroop, Klocke, Barbara J., Gillespie, G. Yancey, Shevde, Lalita A., Carroll, Steven L., and Roth, Kevin A.
- Abstract
Glioblastomas (GBMs) are the most common and aggressive primary human malignant brain tumors. 4-Hydroxy tamoxifen (OHT) is an active metabolite of the tamoxifen (TMX) prodrug and a well-established estrogen receptor (ER) and estrogen-related receptor antagonist. A recent study from our laboratory demonstrated that OHT induced ER-independent malignant peripheral nerve sheath tumor (MPNST) cell death by autophagic degradation of the prosurvival protein Kirsten rat sarcoma viral oncogene homolog. Because both MPNST and GBM are glial in cell origin, we hypothesized that OHT could mediate similar effects in GBM. OHT induced a concentration-dependent reduction in cell viability that was largely independent of caspase activation in a human GBM cell line and 2 patient-derived xenolines. Further, OHT induced both cytotoxic autophagy and a concentration-dependent decrease in epidermal growth factor receptor (EGFR) protein levels. A GBM cell line expressing EGFR variant III (EGFRvIII) was relatively resistant to OHT-induced death and EGFRvIII was refractory to OHT-induced degradation. Thus, OHT induces GBM cell death through a caspase-independent, autophagy-related mechanism and should be considered as a potential therapeutic agent in patients with GBM whose tumors express wild-type EGFR.
- Published
- 2016
- Full Text
- View/download PDF
265. Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma.
- Author
-
Bauer, David F., Pereboeva, Larisa, Gillespie, G. Yancey, Cloud, Gretchen A., Elzafarany, Osama, Langford, Catherine, Markert, James M., Jr., Lawrence S. Lamb, and Lamb, Lawrence S Jr
- Subjects
- *
INTRACRANIAL tumors , *NEUROBLASTOMA , *HERPES simplex vaccines , *CANCER vaccines , *INTERLEUKIN-12 , *IMMUNOCOMPETENT cells , *LABORATORY mice , *VACCINATION , *TUMOR treatment , *THERAPEUTICS , *BRAIN tumor treatment , *LYMPHOCYTE metabolism , *ANIMALS , *BIOLOGICAL models , *BRAIN tumors , *CELL lines , *CELLULAR immunity , *GENES , *HERPESVIRUSES , *IMMUNITY , *IMMUNIZATION , *IMMUNOPHENOTYPING , *INTERLEUKINS , *LYMPHOCYTES , *MICE , *SURVIVAL analysis (Biometry) , *VIRUSES , *PHENOTYPES , *TREATMENT effectiveness , *TUMOR grading - Abstract
We designed multimodal tumor vaccine that consists of irradiated tumor cells infected with the oncolytic IL-12-expressing HSV-1 virus, M002. This vaccine was tested against the syngeneic neuroblastoma mouse model Neuro 2a injected into the right caudate nucleus of the immunocompetent A/J mice. Mice were vaccinated via intramuscular injection of multimodal vaccine or uninfected irradiated tumor cells at seven and 14 days after tumor establishment. While there was no survival difference between groups vaccinated with cell-based vaccine applied following tumor injection, a premunition prime/boost vaccination strategy produced a significant survival advantage in both groups and sustained immune response to an intracranial rechallenge of the same tumor. The syngeneic but unrelated H6 hepatocellular tumor cell line grew unrestricted in vaccinated mice, indicative of vaccine-mediated specific immunity to Neuro 2a tumors. Longitudinal analyses of tumor-infiltrating lymphocytes revealed a primary adaptive T cell response involving both CD4+ and CD8+ T cell subsets. Spleen cell mononuclear preparations from vaccinated mice were significantly more cytotoxic to Neuro 2a tumor cells than spleen cells from control mice as demonstrated in a four-hour in vitro cytotoxicity assay. These results strongly suggest that an irradiated whole cell tumor vaccine incorporating IL-12-expressing M002 HSV can produce a durable, specific immunization in a murine model of intracranial tumor. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
266. GLIOBLASTOMA INVASION CAN BE BLOCKED BY NONTOXIC INHIBITORS OF INTEGRIN AND MYOSIN FUNCTION.
- Author
-
Rosenfeld, Steven S. and Gillespie, G. Yancey
- Published
- 1996
- Full Text
- View/download PDF
267. Combined Efficacy of Cediranib and Quinacrine in Glioma Is Enhanced by Hypoxia and Causally Linked to Autophagic Vacuole Accumulation.
- Author
-
Lobo, Merryl R., Wang, Xiaoyan, Gillespie, G. Yancey, Woltjer, Randall L., and Pike, Martin M.
- Subjects
- *
GLIOMA treatment , *QUINAZOLINE , *QUINACRINE , *DRUG efficacy , *HYPOXEMIA , *AUTOPHAGY , *THERAPEUTICS - Abstract
We have previously reported that the in vivo anti-glioma efficacy of the anti-angiogenic receptor tyrosine kinase inhibitor cediranib is substantially enhanced via combination with the late-stage autophagy inhibitor quinacrine. The current study investigates the role of hypoxia and autophagy in combined cediranib/quinacrine efficacy. EF5 immunostaining revealed a prevalence of hypoxia in mouse intracranial 4C8 glioma, consistent with high-grade glioma. MTS cell viability assays using 4C8 glioma cells revealed that hypoxia potentiated the efficacy of combined cediranib/quinacrine: cell viability reductions induced by 1 µM cediranib +2.5 µM quinacrine were 78±7% (hypoxia) vs. 31±3% (normoxia), p<0.05. Apoptosis was markedly increased for cediranib/quinacrine/hypoxia versus all other groups. Autophagic vacuole biomarker LC3-II increased robustly in response to cediranib, quinacrine, or hypoxia. Combined cediranib/quinacrine increased LC3-II further, with the largest increases occurring with combined cediranib/quinacrine/hypoxia. Early stage autophagy inhibitor 3-MA prevented LC3-II accumulation with combined cediranib/quinacrine/hypoxia and substantially attenuated the associated reduction in cell viability. Combined efficacy of cediranib with bafilomycin A1, another late-stage autophagy inhibitor, was additive but lacked substantial potentiation by hypoxia. Substantially lower LC3-II accumulation was observed with bafilomycin A1 in comparison to quinacrine. Cediranib and quinacrine each strongly inhibited Akt phosphoryation, while bafilomycin A1 had no effect. Our results provide compelling evidence that autophagic vacuole accumulation plays a causal role in the anti-glioma cytotoxic efficacy of combined cediranib/quinacrine. Such accumulation is likely related to stimulation of autophagosome induction by hypoxia, which is prevalent in the glioma tumor microenvironment, as well as Akt signaling inhibition from both cediranib and quinacrine. Quinacrine's unique ability to inhibit both Akt and autophagic vacuole degradation may enhance its ability to drive cytotoxic autophagic vacuole accumulation. These findings provide a rationale for a clinical evaluation of combined cediranib/quinacrine therapy for malignant glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
268. Adenovirus-Mediated Transfer of BAX Driven by the Vascular Endothelial Growth Factor Promoter Induces Apoptosis in Lung Cancer Cells
- Author
-
Kaliberov, Sergey A., Buchsbaum, Donald J., Gillespie, G. Yancey, Curiel, David T., Arafat, Waleed O., Carpenter, Mark, and Stackhouse, Murray A.
- Subjects
- *
APOPTOSIS , *GENE therapy , *CANCER treatment - Abstract
Apoptosis induction is a promising approach for cancer gene therapy. Bax is a death-promoting member of the Bcl2 family of genes that are intimately involved in apoptosis. Overexpression of BAX protein can accelerate cell death by homodimers that promote apoptosis in a variety of cancer cell lines. The cytotoxic effect of BAX was evaluated in vitro by a recombinant adenovirus system expressing the human BAX gene under control of human vascular endothelial growth factor (VEGF) promoter element (AdVEGFBAX). Overexpression of BAX in human lung carcinoma cells resulted in apoptosis induction, caspase activation, and cell growth suppression, none of which were observed in BEAS-2B normal human bronchial epithelial cells that do not overexpress VEGF under normoxic conditions. To examine the hypoxia responsiveness of the VEGF promoter, lung cancer cells were transiently exposed to hypoxia; this treatment increased enhanced green fluorescent protein (EGFP) expression after AdVEGFEGFP infection in both normal and cancer cell lines, and enhanced apoptosis and decreased the number of surviving cancer cells compared with the Ad/BAX plus Ad/Cre binary adenoviral system. These results suggest a possible therapeutic application of cancer-specific expression of the pro-apoptotic Bax gene driven by the VEGF promoter. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
269. A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
- Author
-
Lamb, Lawrence S., Pereboeva, Larisa, Youngblood, Samantha, Gillespie, G. Yancey, Nabors, L. Burton, Markert, James M., Dasgupta, Anindya, Langford, Catherine, and Spencer, H. Trent
- Subjects
- *
T cells , *TEMOZOLOMIDE , *SURVIVAL rate , *GLIOMAS , *ALKYLATING agents , *DNA methyltransferases - Abstract
Chemotherapeutic drugs such as the alkylating agent Temozolomide (TMZ), in addition to reducing tumor mass, can also sensitize tumors to immune recognition by transient upregulation of multiple stress induced NKG2D ligands (NKG2DL). However, the potential for an effective response by innate lymphocyte effectors such as NK and γδ T cells that recognize NKG2DL is limited by the drug's concomitant lymphodepleting effects. We have previously shown that modification of γδ T cells with a methylguanine DNA methyltransferase (MGMT) transgene confers TMZ resistance via production of O6-alkylguanine DNA alkyltransferase (AGT) thereby enabling γδ T cell function in therapeutic concentrations of TMZ. In this study, we tested this strategy which we have termed Drug Resistant Immunotherapy (DRI) to examine whether combination therapy of TMZ and MGMT-modified γδ T cells could improve survival outcomes in four human/mouse xenograft models of primary and refractory GBM. Our results confirm that DRI leverages the innate response of γδ T cells to chemotherapy-induced stress associated antigen expression and achieves synergies that are significantly greater than either individual approach. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
270. Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model.
- Author
-
Kasten, Benjamin B., Houson, Hailey A., Coleman, Jennifer M., Leavenworth, Jianmei W., Markert, James M., Wu, Anna M., Salazar, Felix, Tavaré, Richard, Massicano, Adriana V. F., Gillespie, G. Yancey, Lapi, Suzanne E., Warram, Jason M., and Sorace, Anna G.
- Subjects
- *
POSITRON emission tomography , *CD8 antigen , *GLIOMAS , *ONCOLYTIC virotherapy , *LABORATORY mice - Abstract
Determination of treatment response to immunotherapy in glioblastoma multiforme (GBM) is a process which can take months. Detection of CD8+ T cell recruitment to the tumor with a noninvasive imaging modality such as positron emission tomography (PET) may allow for tumor characterization and early evaluation of therapeutic response to immunotherapy. In this study, we utilized 89Zr-labeled anti-CD8 cys-diabody-PET to provide proof-of-concept to detect CD8+ T cell immune response to oncolytic herpes simplex virus (oHSV) M002 immunotherapy in a syngeneic GBM model. Immunocompetent mice (n = 16) were implanted intracranially with GSC005 GBM tumors, and treated with intratumoral injection of oHSV M002 or saline control. An additional non-tumor bearing cohort (n = 4) receiving oHSV M002 treatment was also evaluated. Mice were injected with 89Zr-labeled anti-CD8 cys-diabody seven days post oHSV administration and imaged with a preclinical PET scanner. Standardized uptake value (SUV) was quantified. Ex vivo tissue analyses included autoradiography and immunohistochemistry. PET imaging showed significantly higher SUV in tumors which had been treated with M002 compared to those without M002 treatment (p = 0.0207) and the non-tumor bearing M002 treated group (p = 0.0021). Accumulation in target areas, especially the spleen, was significantly reduced by blocking with the non-labeled diabody (p < 0.001). Radioactive probe accumulation in brains was consistent with CD8+ cell trafficking patterns after oHSV treatment. This PET imaging strategy could aid in distinguishing responders from non-responders during immunotherapy of GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
271. N-cadherin upregulation mediates adaptive radioresistance in glioblastoma.
- Author
-
Satoru Osuka, Dan Zhu, Zhaobin Zhang, Chaoxi Li, Stackhouse, Christian T., Sampetrean, Oltea, Olson, Jeffrey J., Gillespie, G. Yancey, Hideyuki Saya, Willey, Christopher D., Van Meir, Erwin G., Osuka, Satoru, Zhu, Dan, Zhang, Zhaobin, Li, Chaoxi, and Saya, Hideyuki
- Subjects
- *
GLIOBLASTOMA multiforme , *CELL populations , *METHYLGUANINE , *STEM cells , *CADHERINS , *CELL proliferation , *PHENOTYPES , *BIOCHEMISTRY , *RESEARCH , *ANIMAL experimentation , *RESEARCH methodology , *RADIATION , *GLIOMAS , *CELL physiology , *APOPTOSIS , *MEDICAL cooperation , *EVALUATION research , *BRAIN tumors , *PHYSIOLOGICAL adaptation , *CELLULAR signal transduction , *PHENOMENOLOGY , *COMPARATIVE studies , *GLYCOPROTEINS , *RESEARCH funding , *CELL lines , *GENETIC techniques , *ANTIGENS , *MICE , *CHEMICAL inhibitors - Abstract
Glioblastoma (GBM) is composed of heterogeneous tumor cell populations, including those with stem cell properties, termed glioma stem cells (GSCs). GSCs are innately less radiation sensitive than the tumor bulk and are believed to drive GBM formation and recurrence after repeated irradiation. However, it is unclear how GSCs adapt to escape the toxicity of repeated irradiation used in clinical practice. To identify important mediators of adaptive radioresistance in GBM, we generated radioresistant human and mouse GSCs by exposing them to repeat cycles of irradiation. Surviving subpopulations acquired strong radioresistance in vivo, which was accompanied by a reduction in cell proliferation and an increase in cell-cell adhesion and N-cadherin expression. Increasing N-cadherin expression rendered parental GSCs radioresistant, reduced their proliferation, and increased their stemness and intercellular adhesive properties. Conversely, radioresistant GSCs lost their acquired phenotypes upon CRISPR/Cas9-mediated knockout of N-cadherin. Mechanistically, elevated N-cadherin expression resulted in the accumulation of β-catenin at the cell surface, which suppressed Wnt/β-catenin proliferative signaling, reduced neural differentiation, and protected against apoptosis through Clusterin secretion. N-cadherin upregulation was induced by radiation-induced IGF1 secretion, and the radiation resistance phenotype could be reverted with picropodophyllin, a clinically applicable blood-brain-barrier permeable IGF1 receptor inhibitor, supporting clinical translation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
272. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
- Author
-
Bernstock, Joshua D., Bag, Asim K., Fiveash, John, Kachurak, Kara, Elsayed, Galal, Chagoya, Gustavo, Gessler, Florian, Valdes, Pablo A., Madan-Swain, Avi, Whitley, Richard, Markert, James M., Gillespie, G. Yancey, Johnston, James M., and Friedman, Gregory K.
- Subjects
- *
CEREBELLAR tumors , *BRAIN tumors , *INFRATENTORIAL brain tumors , *CLINICAL trials , *HERPES simplex virus , *ARACHNOID cysts , *RADIOBIOLOGY - Abstract
Brain tumors represent the most common pediatric solid neoplasms and leading cause of childhood cancer-related morbidity and mortality. Although most adult brain tumors are supratentorial and arise in the cerebrum, the majority of pediatric brain tumors are infratentorial and arise in the posterior fossa, specifically the cerebellum. Outcomes from malignant cerebellar tumors are unacceptable despite aggressive treatments (surgery, radiation, and/or chemotherapy) that are harmful to the developing brain. Novel treatments/approaches such as oncolytic virotherapy are urgently needed. Preclinical and prior clinical studies suggest that genetically engineered oncolytic herpes simplex virus (HSV-1) G207 can safely target cerebellar malignancies and has potential to induce an antitumor immune response at local and distant sites of disease, including spinal metastases and leptomeningeal disease. Herein, we outline the rationale, design, and significance of a first-in-human immunotherapy Phase 1 clinical trial targeting recurrent cerebellar malignancies with HSV G207 combined with a single low-dose of radiation (5 Gy), designed to enhance virus replication and innate and adaptive immune responses. We discuss the unique challenges of inoculating virus through intratumoral catheters into cerebellar tumors. The trial utilizes a single arm open-label traditional 3 + 3 design with four dose cohorts. The primary objective is to assess safety and tolerability of G207 with radiation in recurrent/progressive malignant pediatric cerebellar tumors. After biopsy to prove recurrence/progression, one to four intratumoral catheters will be placed followed by a controlled-rate infusion of G207 for 6 h followed by the removal of catheters at the bedside. Radiation will be given within 24 h of virus inoculation. Patients will be monitored closely for toxicity and virus shedding. Efficacy will be assessed by measuring radiographic response, performance score, progression-free and overall survival, and quality of life. The data obtained will be invaluable in our efforts to produce more effective and less toxic therapies for children with high-grade brain tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
273. Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models.
- Author
-
Kasten, Benjamin B., Jiang, Ke, Cole, Denzel, Jani, Aditi, Udayakumar, Neha, Gillespie, G. Yancey, Lu, Guolan, Dai, Tingting, Rosenthal, Eben L., Markert, James M., Rao, Jianghong, and Warram, Jason M.
- Subjects
- *
FLUORODEOXYGLUCOSE F18 , *DUAL fluorescence , *ANIMAL models in research , *IMMUNOFLUORESCENCE , *POSITRON emission tomography , *GLIOMAS - Abstract
Purpose: There is a clinical need for agents that target glioma cells for non-invasive and intraoperative imaging to guide therapeutic intervention and improve the prognosis of glioma. Matrix metalloproteinase (MMP)-14 is overexpressed in glioma with negligible expression in normal brain, presenting MMP-14 as an attractive biomarker for imaging glioma. In this study, we designed a peptide probe containing a near-infrared fluorescence (NIRF) dye/quencher pair, a positron emission tomography (PET) radionuclide, and a moiety with high affinity to MMP-14. This novel substrate-binding peptide allows dual modality imaging of glioma only after cleavage by MMP-14 to activate the quenched NIRF signal, enhancing probe specificity and imaging contrast. Methods: MMP-14 expression and activity in human glioma tissues and cells were measured in vitro by immunofluorescence and gel zymography. Cleavage of the novel substrate and substrate-binding peptides by glioma cells in vitro and glioma xenograft tumors in vivo was determined by NIRF imaging. Biodistribution of the radiolabeled MMP-14-binding peptide or substrate-binding peptide was determined in mice bearing orthotopic patient-derived xenograft (PDX) glioma tumors by PET imaging. Results: Glioma cells with MMP-14 activity showed activation and retention of NIRF signal from the cleaved peptides. Resected mouse brains with PDX glioma tumors showed tumor-to-background NIRF ratios of 7.6–11.1 at 4 h after i.v. injection of the peptides. PET/CT images showed localization of activity in orthotopic PDX tumors after i.v. injection of 68Ga-binding peptide or 64Cu-substrate-binding peptide; uptake of the radiolabeled peptides in tumors was significantly reduced (p < 0.05) by blocking with the non-labeled-binding peptide. PET and NIRF signals correlated linearly in the orthotopic PDX tumors. Immunohistochemistry showed co-localization of MMP-14 expression and NIRF signal in the resected tumors. Conclusions: The novel MMP-14 substrate-binding peptide enabled PET/NIRF imaging of glioma models in mice, warranting future image-guided resection studies with the probe in preclinical glioma models. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
274. Chapter 4 - Separation of Host Cells Infiltrating Tumors and Allografts by Velocity Sedimentation at Unit Gravity
- Author
-
GILLESPIE, G. YANCEY
- Published
- 1982
- Full Text
- View/download PDF
275. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
- Author
-
Thomas, Eric D., Meza-Perez, Selene, Bevis, Kerri S., Randall, Troy D., Gillespie, G. Yancey, Langford, Catherine, and Alvarez, Ronald D.
- Subjects
- *
OVARIAN cancer treatment , *HERPES simplex virus , *INTERLEUKIN-12 , *GENE expression , *ANTINEOPLASTIC agents , *LABORATORY mice - Abstract
Background: Despite advances in surgical aggressiveness and conventional chemotherapy, ovarian cancer remains the most lethal cause of gynecologic cancer mortality; consequently there is a need for new therapeutic agents and innovative treatment paradigms for the treatment of ovarian cancer. Several studies have demonstrated that ovarian cancer is an immunogenic disease and immunotherapy represents a promising and novel approach that has not been completely evaluated in ovarian cancer. Our objective was to evaluate the anti-tumor activity of an oncolytic herpes simplex virus "armed" with murine interleukin-12 and its ability to elicit tumor-specific immune responses. We evaluated the ability of interleukin−12-expressing and control oncolytic herpes simplex virus to kill murine and human ovarian cancer cell lines in vitro. We also administered interleukin−12-expressing oncolytic herpes simplex virus to the peritoneal cavity of mice that had developed spontaneous, metastatic ovarian cancer and determined overall survival and tumor burden at 95 days. We used flow cytometry to quantify the tumor antigen-specific CD8+ T cell response in the omentum and peritoneal cavity. Results: All ovarian cancer cell lines demonstrated susceptibility to oncolytic herpes simplex virus in vitro. Compared to controls, mice treated with interleukin−12-expressing oncolytic herpes simplex virus demonstrated a more robust tumor antigen-specific CD8+ T-cell immune response in the omentum (471.6 cells vs 33.1 cells; p = 0.02) and peritoneal cavity (962.3 cells vs 179.5 cells; p = 0.05). Compared to controls, mice treated with interleukin−12-expressing oncolytic herpes simplex virus were more likely to control ovarian cancer metastases (81.2% vs 18.2%; p = 0.008) and had a significantly longer overall survival (p = 0.02). Finally, five of 6 mice treated with interleukin−12-expressing oHSV had no evidence of metastatic tumor when euthanized at 6 months, compared to two of 4 mice treated with sterile phosphate buffer solution. Conclusion: Our pilot study demonstrates that an interleukin−12-expressing oncolytic herpes simplex virus effectively kills both murine and human ovarian cancer cell lines and promotes tumor antigen-specific CD8+ T-cell responses in the peritoneal cavity and omentum, leading to reduced peritoneal metastasis and improved survival in a mouse model. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
276. A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents.
- Author
-
Dobbins, G. Clement, Ugai, Hideyo, Curiel, David T., and Gillespie, G. Yancey
- Subjects
- *
ADENOVIRUSES , *VIRAL replication , *IMMUNOTHERAPY , *PROTEIN expression , *CELL lines - Abstract
Studies have demonstrated that oncolytic adenoviruses based on a 24 base pair deletion in the viral E1A gene (D24) may be promising therapeutics for treating a number of cancer types. In order to increase the therapeutic potential of these oncolytic viruses, a novel conditionally replicating adenovirus targeting multiple receptors upregulated on tumors was generated by incorporating an Ad5/3 fiber with a carboxyl terminus RGD ligand. The virus displayed full cytopathic effect in all tumor lines assayed at low titers with improved cytotoxicity over Ad5-RGD D24, Ad5/3 D24 and an HSV oncolytic virus. The virus was then engineered to deliver immunotherapeutic agents such as GM-CSF while maintaining enhanced heterogenic oncolysis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
277. Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
- Author
-
Lobo, Merryl R., Kukino, Ayaka, Tran, Huong, Schabel, Matthias C., Jr.Springer, Charles S., Gillespie, G. Yancey, Grafe, Marjorie R., Woltjer, Randall L., and Pike, Martin M.
- Subjects
- *
ANTINEOPLASTIC agents , *PROTEIN-tyrosine kinase inhibitors , *GLIOMAS , *DRUG synergism , *PROTEASOMES , *LABORATORY mice - Abstract
Prognosis remains extremely poor for malignant glioma. Targeted therapeutic approaches, including single agent anti-angiogenic and proteasome inhibition strategies, have not resulted in sustained anti-glioma clinical efficacy. We tested the anti-glioma efficacy of the anti-angiogenic receptor tyrosine kinase inhibitor cediranib and the novel proteasome inhibitor SC68896, in combination and as single agents. To assess anti-angiogenic effects and evaluate efficacy we employed 4C8 intracranial mouse glioma and a dual-bolus perfusion MRI approach to measure Ktrans, relative cerebral blood flow and volume (rCBF, rCBV), and relative mean transit time (rMTT) in combination with anatomical MRI measurements of tumor growth. While single agent cediranib or SC68896 treatment did not alter tumor growth or survival, combined cediranib/SC68896 significantly delayed tumor growth and increased median survival by 2-fold, compared to untreated. This was accompanied by substantially increased tumor necrosis in the cediranib/SC68896 group (p<0.01), not observed with single agent treatments. Mean vessel density was significantly lower, and mean vessel lumen area was significantly higher, for the combined cediranib/SC68896 group versus untreated. Consistent with our previous findings, cediranib alone did not significantly alter mean tumor rCBF, rCBV, rMTT, or Ktrans. In contrast, SC68896 reduced rCBF in comparison to untreated, but without concomitant reductions in rCBV, rMTT, or Ktrans. Importantly, combined cediranib/SC68896 substantially reduced rCBF, rCBV. rMTT, and Ktrans. A novel analysis of Ktrans/rCBV suggests that changes in Ktrans with time and/or treatment are related to altered total vascular surface area. The data suggest that combined cediranib/SC68896 induced potent anti-angiogenic effects, resulting in increased vascular efficiency and reduced extravasation, consistent with a process of vascular normalization. The study represents the first demonstration that the combination of cediranib with a proteasome inhibitor substantially increases the anti-angiogenic efficacy produced from either agent alone, and synergistically slows glioma tumor growth and extends survival, suggesting a promising treatment which warrants further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
278. Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW.
- Author
-
Warram, Jason M., de Boer, Esther, Korb, Melissa, Hartman, Yolanda, Kovar, Joy, Markert, James M., Gillespie, G. Yancey, and Rosenthal, Eben L.
- Subjects
- *
GLIOMA treatment , *GLIOBLASTOMA multiforme treatment , *NERVOUS system tumors , *CETUXIMAB ,TUMOR surgery - Abstract
The standard treatment for glioblastoma multiforme (GBM) remains maximal safe surgical resection. Here, we evaluated the ability of a systemically administered antibody–dye probe conjugate (cetuximab-IRDye 800CW) to provide sufficient fluorescent contrast for surgical resection of disease in both subcutaneous and orthotopic animal models of GBM. Multiple luciferase-positive GBM cell lines (D-54MG, U-87MG, and U-251MG; n = 5) were implanted in mouse flank and tumors were fluorescently imaged daily using a closed-field near-infrared (NIR) system after cetuximab-IRDye 800CW systemic administration. Orthotopic models were also generated (n = 5), and tumor resection was performed under white light and fluorescence guidance using an FDA-approved wide-field NIR imaging system. Residual tumor was monitored using luciferase imaging. Immunohistochemistry was performed to characterize tumor fluorescence, epidermal growth factor receptor (EGFR) expression, and vessel density. Daily imaging of tumors revealed an average tumor-to-background (TBR) of 4.5 for U-87MG, 4.1 for D-54MG, and 3.7 for U-251MG. Fluorescence intensity within the tumors peaked on day-1 after cetuximab-IRDye 800CW administration, however the TBR increased over time in two of the three cell lines. For the orthotopic model, TBR on surgery day ranged from 19 to 23 during wide-field, intraoperative imaging. Surgical resection under white light on day 3 after cetuximab-IRDye 800CW resulted in an average 41% reduction in luciferase signal while fluorescence-guided resection using wide-field NIR imaging resulted in a significantly (P = 0.001) greater reduction in luciferase signal (87%). Reduction of luciferase signal was found to correlate (R2 = 0.99) with reduction in fluorescence intensity. Fluorescence intensity was found to correlate (P < 0.05) with EGFR expression in D-54MG and U-251MG tumor types but not U-87MG. However, tumor fluorescence was found to correlate with vessel density for the U-87MG tumors. Here we show systemic administration of cetuximab-IRDye 800CW in combination with wide-field NIR imaging provided robust and specific fluorescence contrast for successful localization of disease in subcutaneous and orthotopic animal models of GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
279. ROCK Inhibition Facilitates In Vitro Expansion of Glioblastoma Stem-Like Cells.
- Author
-
Tilson, Samantha G., Haley, Elizabeth M., Triantafillu, Ursula L., Dozier, David A., Langford, Catherine P., Gillespie, G. Yancey, and Kim, Yonghyun
- Subjects
- *
GLIOBLASTOMA multiforme , *CANCER stem cells , *CANCER radiotherapy , *ENZYME inhibitors , *CANCER cells , *APOPTOSIS - Abstract
Due to their stem-like characteristics and their resistance to existing chemo- and radiation therapies, there is a growing appreciation that cancer stem cells (CSCs) are the root cause behind cancer metastasis and recurrence. However, these cells represent a small subpopulation of cancer cells and are difficult to propagate in vitro. Glioblastoma is an extremely deadly form of brain cancer that is hypothesized to have a subpopulation of CSCs called glioblastoma stem cells (GSCs; also called brain tumor initiating cells, BTICs). We propose the use of selective Rho-kinase (ROCK) inhibitors, Y-27632 and fasudil, to promote GSC/BTIC-like cell survival and propagation in vitro. ROCK inhibitors have been implicated in suppressing apoptosis, and it was hypothesized that they would increase the number of GSC/BTIC-like cells grown in vitro and improve cloning efficiencies. Indeed, our data demonstrate that transient and continuous supplementation of non-toxic concentrations of Y-27632 and fasudil inhibited apoptosis, enhanced the cells’ ability to form spheres, and increased stem cell marker expressing GSC/BTIC-like cell subpopulation. Our data indicated that pharmacological and genetic (siRNA) inhibitions of the ROCK pathway facilitates in vitro expansion of GSC/BTIC-like cells. Thus, ROCK pathway inhibition shows promise for future optimization of CSC culture media. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
280. Dynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma.
- Author
-
Beck, Benjamin H., Kim, Hyunggoon, O’Brien, Rebecca, Jadus, Martin R., Gillespie, G. Yancey, Cloud, Gretchen A., Hoa, Neil T., Langford, Catherine P., Lopez, Richard D., Harkins, Lualhati E., and Lamb Jr., Lawrence S.
- Subjects
- *
T cells , *IMMUNOCOMPETENT cells , *GLIOMAS , *LABORATORY mice , *XENOGRAFTS , *ANNEXINS - Abstract
Human γδ T cells are potent effectors against glioma cell lines in vitro and in human/mouse xenograft models of glioblastoma, however, this effect has not been investigated in an immunocompetent mouse model. In this report, we established GL261 intracranial gliomas in syngeneic WT C57BL/6 mice and measured circulating γδ T cell count, phenotype, Vγ/Vδ repertoire, tumor histopathology, NKG2D ligands expression, and T cell invasion at day 10–12 post-injection and at end stage. Circulating γδ T cells transiently increased and upregulated Annexin V expression at post-tumor day 10–12 followed by a dramatic decline in γδ T cell count at end stage. T cell receptor repertoire showed no changes in Vγ1, Vγ4, Vγ7 or Vδ1 subsets from controls at post-tumor day 10–12 or at end stage except for an end-stage increase in the Vδ4 population. Approximately 12% of γδ T cells produced IFN-γ. IL-17 and IL-4 producing γδ T cells were not detected. Tumor progression was the same in TCRδ-/- C57BL/6 mice as that observed in WT mice, suggesting that γδ T cells exerted neither a regulatory nor a sustainable cytotoxic effect on the tumor. WT mice that received an intracranial injection of γδ T cells 15m following tumor placement showed evidence of local tumor growth inhibition but this was insufficient to confer a survival advantage over untreated controls. Taken together, our findings suggest that an early nonspecific proliferation of γδ T cells followed by their depletion occurs in mice implanted with syngeneic GL261 gliomas. The mechanism by which γδ T cell expansion occurs remains a subject for further investigation of the mechanisms responsible for this immune response in the setting of high-grade glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
281. Oncolytic viral therapy: targeting cancer stem cells.
- Author
-
Smith, Tyrel T., Roth, Justin C., Friedman, Gregory K., and Gillespie, G. Yancey
- Published
- 2014
- Full Text
- View/download PDF
282. Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain.
- Author
-
Radbill, Andrew E., Reddy, Alyssa T., Markert, James M., Wyss, J. Michael, Pike, Martin M., Akella, N. Shastry, Bharara, Niteesh, and Gillespie, G. Yancey
- Subjects
- *
ONCOGENIC viruses , *TUMORS , *BRAIN cancer , *HERPES simplex , *MAGNETIC resonance imaging , *JUVENILE diseases - Abstract
Viral oncolytic therapy for malignant brain tumors involves local intratumoral delivery of a genetically engineered virus with tumor cell-specific lytic activity. Promising preliminary results have been achieved in preclinical models with G207, a replication-competent herpes simplex virus type 1 constructed with multiple directed mutations. Although the safety of G207 has been demonstrated in adults, application of viral oncolytic therapy to children with brain tumors has been delayed because of previous lack of data concerning the impact of a replication-competent oncolytic virus on the developing mammalian brain. In this study there was no significant difference in long-term physical development, cognitive performance, or exploratory behaviors between mice that received intracerebral inoculation of G207 or control saline at 4 days of age. However, histological examination and magnetic resonance imaging revealed frequent unilateral ventriculomegaly ipsilateral to the site of injection in only the G207 group. These results suggest that although it is unlikely that G207 will have significant adverse effects on neurodevelopmental outcomes of pediatric patients with brain tumors, an initial study of G207 in children should exclude those patients with tumors in or near the ventricular system as well as patients less than 2 years of age. Furthermore, patients in such a study will need to be closely monitored for the development of hydrocephalus. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
283. Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates
- Author
-
Parker, Jacqueline N., Pfister, Luz-Andrea, Quenelle, Debra, Gillespie, G. Yancey, Markert, James M., Kern, Earl R., and Whitley, Richard J.
- Subjects
- *
HERPES simplex virus , *HERPESVIRUS diseases , *VIRUS diseases , *CHICKENPOX - Abstract
Abstract: We are using genetically modified, conditionally replicating herpes simplex virus (HSV) that express either interleukin (IL)-12 or granulocyte macrophage-colony stimulating factor (GM-CSF) as live, attenuated vaccine candidates for protection against HSV infection and/or disease. We report the following: (1) animals previously vaccinated with these candidate vaccines exhibited dose-dependent protection after intranasal, intraperitoneal or intracranial challenge with the highly virulent E377-MB wild-type HSV-1; (2) the IL-12 expressing virus (M002) consistently conferred protection at lower immunization doses than GM-CSF expressing virus (M004); (3) between 80 and 100% protection from E377-MB challenge was conferred after intramuscular immunization of mice with any of the three Δγ134.5 HSV, as opposed to 50% protection elicited after immunization with wild-type HSV-1 (F); and (4) latent virus was not detected at a higher rate in animals immunized and subsequently challenged with E377-MB than in immunized animals alone. These data suggest that conditionally replicating, cytokine-expressing HSV are able to elicit protective immune responses while retaining safety in an experimental murine model. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
284. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12.
- Author
-
Parker, Jacqueline N, Meleth, Sreelatha, Hughes, Kenneth B, Gillespie, G Yancey, Whitley, Richard J, and Markert, James M
- Subjects
- *
VIRAL replication , *ANTINEOPLASTIC agents , *MOUSE diseases , *IMMUNOHISTOCHEMISTRY , *MOUSE leukemia , *HERPES simplex virus , *IMMUNOCHEMISTRY - Abstract
Herpes simplex viruses type 1 (HSV-1) that lack the?134.5 gene are unable to replicate in the central nervous system (CNS), but maintain replication competence in actively dividing tumors. To determine if antitumor therapy by M002, a?134.5- HSV that expresses interleukin-12 (IL-12), could be augmented by combinatorial therapy with another?134.5-deleted HSV-1 engineered to express the chemokine CCL2, Neuro-2a tumors were established subcutaneously in the syngeneic A/J mouse strain. Tumors received multiple injections intratumorally either of saline, the parent, non-cytokine-expressing virus R3659, M002, M010 (?134.5- HSV expressing CCL2), or a combination of M002 and M010. Efficacies were evaluated by monitoring inhibition of tumor growth over time. Results demonstrated the following: (1) inhibition of tumor growth was most pronounced in tumors treated with a combination of M002 and M010; (2) enhanced tumor growth inhibition for the combinatorial treatment group was statistically significant compared to either M002 or M010 alone; and (3) the variability between slopes of the tumor growth rates within an individual treatment group appeared to be virus-dependent, and was reproducible between experiments. Our results demonstrate that combinatorial cytokine/chemokine?134.5- HSV therapies can provide superior antitumor effects in experimental tumors as a model for malignancies arising in the brain.Cancer Gene Therapy (2005) 12, 359-368. doi:10.1038/sj.cgt.7700784 Published online 28 January 2005 [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
285. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits...
- Author
-
Goldman, Corey K., Kendall, Richard L., Cabrera, Gustavo, Soroceanu, Liliana, Heike, Yuji, Gillespie, G. Yancey, Siegal, Gene P., Mao, Xianzhi, Bett, Andrew J., Huckle, William R., Thomas, Kenneth A., and Curiel, David T.
- Subjects
- *
TUMORS , *CELLS , *ANTISENSE DNA , *GROWTH factors , *NEOVASCULARIZATION - Abstract
Provides information on a study which transfected tumor cells with complementary deoxyribonucleic acid (cDNA) encoding the native soluble FLT-1 truncated vascular endothelial growth factor (VEGF) receptor, to block the VEGF-dependent angiogenesis. In-depth look at the VEGF; Importance of neovascularization in the growth of solid tumors; Methodology used to conduct the study; Results of the study.
- Published
- 1998
- Full Text
- View/download PDF
286. Serial Passage through Human Glioma Xenografts Selects for a Δγ134.5 Herpes Simplex Virus Type 1 Mutant That Exhibits Decreased Neurotoxicity and Prolongs Survival of Mice with Experimental Brain Tumors.
- Author
-
Shah, Amish C., Price, Kathleen H., Parker, Jacqueline N., Samuel, Sharon L., Meleth, Sreelatha, Cassady, Kevin A., Gillespie, G. Yancey, Whitley, Richard J., and Markert, James M.
- Subjects
- *
HERPES simplex virus , *NEUROBLASTOMA , *BRAIN tumors , *XENOGRAFTS , *ANTINEOPLASTIC agents - Abstract
Previous studies have described in vitro serial passage of a Δγ134.5 herpes simplex virus type 1 (HSV-1) strain in SK-N-SH neuroblastoma cells and selection of mutants that have acquired the ability to infect and replicate in this previously nonpermissive cell line. Here we describe the selection of a mutant HSV-1 strain by in vivo serial passage, which prolongs survival in two separate experimental murine brain tumor models. Two conditionally replication-competent Δγ134.5 viruses, M002, which expresses murine interleukin-12, and its parent virus, R3659, were serially passaged within human malignant glioma D54-MG cell lines in vitro or flank tumor xenografts in vivo. The major findings are (i) viruses passaged in vivo demonstrate decreased neurovirulence, whereas those passaged in vitro demonstrate a partial recovery of the neurovirulence associated with HSV-1; and (ii) vvD54-M002, the virus selected after in vivo serial passage of M002 in D54-MG tumors, improves survival in two independent murine brain tumor models compared to the parent (unpassaged) M002. Additionally, in vitro-passaged, but not in vivo-passaged, M002 displayed changes in the protein synthesis profile in previously nonpermissive cell lines, as well as early US11 transcription. Thus, a mutant HSV-1 strain expressing a foreign gene can be selected for enhanced antitumor efficacy via in vivo serial passage within flank D54-MG tumor xenografts. The enhanced antitumor efficacy of vvD54-M002 is not due to restoration of protein synthesis or early US11 expression. This finding emphasizes the contribution of the in vivo tumor environment for selecting novel oncolytic HSV specifically adapted for tumor cell destruction in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
287. Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.
- Author
-
Kang KD, Bernstock JD, Totsch SK, Gary SE, Rocco A, Nan L, Li R, Etminan T, Han X, Beierle EA, Eisemann T, Wechsler-Reya RJ, Bae S, Whitley R, Gillespie GY, Markert JM, and Friedman GK
- Subjects
- Mice, Animals, Cell Line, Tumor, Mice, Inbred CBA, Poly I, Herpesvirus 1, Human genetics, Oncolytic Viruses genetics, Oncolytic Virotherapy adverse effects, Oncolytic Virotherapy methods, Brain Neoplasms pathology
- Abstract
Purpose: Oncolytic virotherapy with herpes simplex virus-1 (HSV) has shown promise for the treatment of pediatric and adult brain tumors; however, completed and ongoing clinical trials have utilized intratumoral/peritumoral oncolytic HSV (oHSV) inoculation due to intraventricular/intrathecal toxicity concerns. Intratumoral delivery requires an invasive neurosurgical procedure, limits repeat injections, and precludes direct targeting of metastatic and leptomeningeal disease. To address these limitations, we determined causes of toxicity from intraventricular oHSV and established methods for mitigating toxicity to treat disseminated brain tumors in mice., Experimental Design: HSV-sensitive CBA/J mice received intraventricular vehicle, inactivated oHSV, or treatment doses (1×107 plaque-forming units) of oHSV, and toxicity was assessed by weight loss and IHC. Protective strategies to reduce oHSV toxicity, including intraventricular low-dose oHSV or interferon inducer polyinosinic-polycytidylic acid (poly I:C) prior to oHSV treatment dose, were evaluated and then utilized to assess intraventricular oHSV treatment of multiple models of disseminated CNS disease., Results: A standard treatment dose of intraventricular oHSV damaged ependymal cells via virus replication and induction of CD8+ T cells, whereas vehicle or inactivated virus resulted in no toxicity. Subsequent doses of intraventricular oHSV caused little additional toxicity. Interferon induction with phosphorylation of eukaryotic initiation factor-2α (eIF2α) via intraventricular pretreatment with low-dose oHSV or poly I:C mitigated ependyma toxicity. This approach enabled the safe delivery of multiple treatment doses of clinically relevant oHSV G207 and prolonged survival in disseminated brain tumor models., Conclusions: Toxicity from intraventricular oHSV can be mitigated, resulting in therapeutic benefit. These data support the clinical translation of intraventricular G207., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
288. Author Correction: Failure of human rhombic lip differentiation underlies medulloblastoma formation.
- Author
-
Hendrikse LD, Haldipur P, Saulnier O, Millman J, Sjoboen AH, Erickson AW, Ong W, Gordon V, Coudière-Morrison L, Mercier AL, Shokouhian M, Suárez RA, Ly M, Borlase S, Scott DS, Vladoiu MC, Farooq H, Sirbu O, Nakashima T, Nambu S, Funakoshi Y, Bahcheli A, Diaz-Mejia JJ, Golser J, Bach K, Phuong-Bao T, Skowron P, Wang EY, Kumar SA, Balin P, Visvanathan A, Lee JJY, Ayoub R, Chen X, Chen X, Mungall KL, Luu B, Bérubé P, Wang YC, Pfister SM, Kim SK, Delattre O, Bourdeaut F, Doz F, Masliah-Planchon J, Grajkowska WA, Loukides J, Dirks P, Fèvre-Montange M, Jouvet A, French PJ, Kros JM, Zitterbart K, Bailey SD, Eberhart CG, Rao AAN, Giannini C, Olson JM, Garami M, Hauser P, Phillips JJ, Ra YS, de Torres C, Mora J, Li KKW, Ng HK, Poon WS, Pollack IF, López-Aguilar E, Gillespie GY, Van Meter TE, Shofuda T, Vibhakar R, Thompson RC, Cooper MK, Rubin JB, Kumabe T, Jung S, Lach B, Iolascon A, Ferrucci V, de Antonellis P, Zollo M, Cinalli G, Robinson S, Stearns DS, Van Meir EG, Porrati P, Finocchiaro G, Massimino M, Carlotti CG, Faria CC, Roussel MF, Boop F, Chan JA, Aldinger KA, Razavi F, Silvestri E, McLendon RE, Thompson EM, Ansari M, Garre ML, Chico F, Eguía P, Pérezpeña M, Morrissy AS, Cavalli FMG, Wu X, Daniels C, Rich JN, Jones SJM, Moore RA, Marra MA, Huang X, Reimand J, Sorensen PH, Wechsler-Reya RJ, Weiss WA, Pugh TJ, Garzia L, Kleinman CL, Stein LD, Jabado N, Malkin D, Ayrault O, Golden JA, Ellison DW, Doble B, Ramaswamy V, Werbowetski-Ogilvie TE, Suzuki H, Millen KJ, and Taylor MD
- Published
- 2022
- Full Text
- View/download PDF
289. Failure of human rhombic lip differentiation underlies medulloblastoma formation.
- Author
-
Hendrikse LD, Haldipur P, Saulnier O, Millman J, Sjoboen AH, Erickson AW, Ong W, Gordon V, Coudière-Morrison L, Mercier AL, Shokouhian M, Suárez RA, Ly M, Borlase S, Scott DS, Vladoiu MC, Farooq H, Sirbu O, Nakashima T, Nambu S, Funakoshi Y, Bahcheli A, Diaz-Mejia JJ, Golser J, Bach K, Phuong-Bao T, Skowron P, Wang EY, Kumar SA, Balin P, Visvanathan A, Lee JJY, Ayoub R, Chen X, Chen X, Mungall KL, Luu B, Bérubé P, Wang YC, Pfister SM, Kim SK, Delattre O, Bourdeaut F, Doz F, Masliah-Planchon J, Grajkowska WA, Loukides J, Dirks P, Fèvre-Montange M, Jouvet A, French PJ, Kros JM, Zitterbart K, Bailey SD, Eberhart CG, Rao AAN, Giannini C, Olson JM, Garami M, Hauser P, Phillips JJ, Ra YS, de Torres C, Mora J, Li KKW, Ng HK, Poon WS, Pollack IF, López-Aguilar E, Gillespie GY, Van Meter TE, Shofuda T, Vibhakar R, Thompson RC, Cooper MK, Rubin JB, Kumabe T, Jung S, Lach B, Iolascon A, Ferrucci V, de Antonellis P, Zollo M, Cinalli G, Robinson S, Stearns DS, Van Meir EG, Porrati P, Finocchiaro G, Massimino M, Carlotti CG, Faria CC, Roussel MF, Boop F, Chan JA, Aldinger KA, Razavi F, Silvestri E, McLendon RE, Thompson EM, Ansari M, Garre ML, Chico F, Eguía P, Pérezpeña M, Morrissy AS, Cavalli FMG, Wu X, Daniels C, Rich JN, Jones SJM, Moore RA, Marra MA, Huang X, Reimand J, Sorensen PH, Wechsler-Reya RJ, Weiss WA, Pugh TJ, Garzia L, Kleinman CL, Stein LD, Jabado N, Malkin D, Ayrault O, Golden JA, Ellison DW, Doble B, Ramaswamy V, Werbowetski-Ogilvie TE, Suzuki H, Millen KJ, and Taylor MD
- Subjects
- Cell Lineage, Cerebellum embryology, Cerebellum pathology, Core Binding Factor alpha Subunits genetics, Hedgehog Proteins metabolism, Histone Demethylases, Humans, Ki-67 Antigen metabolism, Muscle Proteins, Mutation, Otx Transcription Factors deficiency, Otx Transcription Factors genetics, Repressor Proteins, T-Box Domain Proteins metabolism, Transcription Factors, Cell Differentiation genetics, Cerebellar Neoplasms classification, Cerebellar Neoplasms genetics, Cerebellar Neoplasms pathology, Medulloblastoma classification, Medulloblastoma genetics, Medulloblastoma pathology, Metencephalon embryology, Metencephalon pathology
- Abstract
Medulloblastoma (MB) comprises a group of heterogeneous paediatric embryonal neoplasms of the hindbrain with strong links to early development of the hindbrain
1-4 . Mutations that activate Sonic hedgehog signalling lead to Sonic hedgehog MB in the upper rhombic lip (RL) granule cell lineage5-8 . By contrast, mutations that activate WNT signalling lead to WNT MB in the lower RL9,10 . However, little is known about the more commonly occurring group 4 (G4) MB, which is thought to arise in the unipolar brush cell lineage3,4 . Here we demonstrate that somatic mutations that cause G4 MB converge on the core binding factor alpha (CBFA) complex and mutually exclusive alterations that affect CBFA2T2, CBFA2T3, PRDM6, UTX and OTX2. CBFA2T2 is expressed early in the progenitor cells of the cerebellar RL subventricular zone in Homo sapiens, and G4 MB transcriptionally resembles these progenitors but are stalled in developmental time. Knockdown of OTX2 in model systems relieves this differentiation blockade, which allows MB cells to spontaneously proceed along normal developmental differentiation trajectories. The specific nature of the split human RL, which is destined to generate most of the neurons in the human brain, and its high level of susceptible EOMES+ KI67+ unipolar brush cell progenitor cells probably predisposes our species to the development of G4 MB., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2022
- Full Text
- View/download PDF
290. An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases.
- Author
-
Stackhouse CT, Anderson JC, Yue Z, Nguyen T, Eustace NJ, Langford CP, Wang J, Rowland JR 4th, Xing C, Mikhail FM, Cui X, Alrefai H, Bash RE, Lee KJ, Yang ES, Hjelmeland AB, Miller CR, Chen JY, Gillespie GY, and Willey CD
- Subjects
- Animals, Disease Models, Animal, Genomics, Humans, Neoplasm Recurrence, Local, Xenograft Model Antitumor Assays, Glioblastoma genetics, Glioblastoma metabolism, Glioblastoma radiotherapy, RNA, Long Noncoding genetics, RNA, Long Noncoding metabolism
- Abstract
Key molecular regulators of acquired radiation resistance in recurrent glioblastoma (GBM) are largely unknown, with a dearth of accurate preclinical models. To address this, we generated 8 GBM patient-derived xenograft (PDX) models of acquired radiation therapy-selected (RTS) resistance compared with same-patient, treatment-naive (radiation-sensitive, unselected; RTU) PDXs. These likely unique models mimic the longitudinal evolution of patient recurrent tumors following serial radiation therapy. Indeed, while whole-exome sequencing showed retention of major genomic alterations in the RTS lines, we did detect a chromosome 12q14 amplification that was associated with clinical GBM recurrence in 2 RTS models. A potentially novel bioinformatics pipeline was applied to analyze phenotypic, transcriptomic, and kinomic alterations, which identified long noncoding RNAs (lncRNAs) and targetable, PDX-specific kinases. We observed differential transcriptional enrichment of DNA damage repair pathways in our RTS models, which correlated with several lncRNAs. Global kinomic profiling separated RTU and RTS models, but pairwise analyses indicated that there are multiple molecular routes to acquired radiation resistance. RTS model-specific kinases were identified and targeted with clinically relevant small molecule inhibitors. This cohort of in vivo RTS patient-derived models will enable future preclinical therapeutic testing to help overcome the treatment resistance seen in patients with GBM.
- Published
- 2022
- Full Text
- View/download PDF
291. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.
- Author
-
Miller KE, Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, Leavenworth JW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER, and Markert JM
- Subjects
- Adult, Aged, Brain Neoplasms immunology, Brain Neoplasms mortality, Female, Glioblastoma immunology, Glioblastoma mortality, Humans, Male, Middle Aged, Neoplasm Recurrence, Local mortality, Survival Rate, Brain Neoplasms genetics, Brain Neoplasms therapy, Clinical Trials, Phase I as Topic, Gene Expression Profiling methods, Glioblastoma genetics, Glioblastoma therapy, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local immunology, Neoplasm Recurrence, Local therapy, Oncolytic Virotherapy methods, Oncolytic Viruses, RNA, Neoplasm genetics, Simplexvirus
- Abstract
Purpose: Previously, clinical trials of experimental virotherapy for recurrent glioblastoma multiforme (GBM) demonstrated that inoculation with a conditionally replication-competent Δγ
1 34.5 oncolytic herpes simplex virus (oHSV), G207, was safe. Following the initial safety study, a phase Ib trial enrolled 6 adult patients diagnosed with GBM recurrence from which tumor tissue was banked for future studies., Patients and Methods: Here, we analyzed tumor RNA sequencing (RNA-seq) data obtained from pre- and posttreatment (collected 2 or 5 days after G207 injection) biopsies from the phase Ib study patients., Results: Using a Spearman rank-order correlation analysis, we identified approximately 500 genes whose expression pattern correlated with survival duration. Many of these genes were enriched for the intrinsic IFN-mediated antiviral and adaptive immune functional responses, including immune cell chemotaxis and antigen presentation to T-cells. Furthermore, we show that the expression of several T-cell-related genes was highest in the patient with the longest survival after G207 inoculation., Conclusions: Our data support that the oHSV-induced type I IFN production and the subsequent recruitment of an adaptive immune response differed between enrolled patients and showed association with survival duration in patients with recurrent malignant glioma after treatment with an early generation oHSV., (©2022 The Authors; Published by the American Association for Cancer Research.)- Published
- 2022
- Full Text
- View/download PDF
292. Author Correction: Positron emission tomography imaging with 89 Zr-labeled anti-CD8 cys-diabody reveals CD8 + cell infiltration during oncolytic virus therapy in a glioma murine model.
- Author
-
Kasten BB, Houson HA, Coleman JM, Leavenworth JW, Markert JM, Wu AM, Salazar F, Tavaré R, Massicano AVF, Gillespie GY, Lapi SE, Warram JM, and Sorace AG
- Published
- 2021
- Full Text
- View/download PDF
293. SON drives oncogenic RNA splicing in glioblastoma by regulating PTBP1/PTBP2 switching and RBFOX2 activity.
- Author
-
Kim JH, Jeong K, Li J, Murphy JM, Vukadin L, Stone JK, Richard A, Tran J, Gillespie GY, Flemington EK, Sobol RW, Lim SS, and Ahn EE
- Subjects
- Animals, Brain Neoplasms metabolism, Brain Neoplasms mortality, Brain Neoplasms pathology, Cell Cycle genetics, Cell Line, Tumor, Cell Proliferation, DNA-Binding Proteins antagonists & inhibitors, DNA-Binding Proteins metabolism, Exons, Gene Expression Regulation, Neoplastic, Glioblastoma metabolism, Glioblastoma mortality, Glioblastoma pathology, Heterogeneous-Nuclear Ribonucleoprotein Group A-B genetics, Heterogeneous-Nuclear Ribonucleoprotein Group A-B metabolism, Heterogeneous-Nuclear Ribonucleoproteins metabolism, Heterografts, Humans, Introns, Mice, Minor Histocompatibility Antigens metabolism, Nerve Tissue Proteins metabolism, Neuroglia metabolism, Neuroglia pathology, Neurons metabolism, Neurons pathology, Polypyrimidine Tract-Binding Protein metabolism, RNA Splicing Factors metabolism, RNA, Messenger genetics, RNA, Messenger metabolism, RNA, Small Interfering genetics, RNA, Small Interfering metabolism, Repressor Proteins metabolism, Signal Transduction, Spheroids, Cellular metabolism, Spheroids, Cellular pathology, Survival Analysis, Brain Neoplasms genetics, DNA-Binding Proteins genetics, Glioblastoma genetics, Heterogeneous-Nuclear Ribonucleoproteins genetics, Minor Histocompatibility Antigens genetics, Nerve Tissue Proteins genetics, Polypyrimidine Tract-Binding Protein genetics, RNA Splicing, RNA Splicing Factors genetics, Repressor Proteins genetics
- Abstract
While dysregulation of RNA splicing has been recognized as an emerging target for cancer therapy, the functional significance of RNA splicing and individual splicing factors in brain tumors is poorly understood. Here, we identify SON as a master regulator that activates PTBP1-mediated oncogenic splicing while suppressing RBFOX2-mediated non-oncogenic neuronal splicing in glioblastoma multiforme (GBM). SON is overexpressed in GBM patients and SON knockdown causes failure in intron removal from the PTBP1 transcript, resulting in PTBP1 downregulation and inhibition of its downstream oncogenic splicing. Furthermore, SON forms a complex with hnRNP A2B1 and antagonizes RBFOX2, which leads to skipping of RBFOX2-targeted cassette exons, including the PTBP2 neuronal exon. SON knockdown inhibits proliferation and clonogenicity of GBM cells in vitro and significantly suppresses tumor growth in orthotopic xenografts in vivo. Collectively, our study reveals that SON-mediated RNA splicing is a GBM vulnerability, implicating SON as a potential therapeutic target in brain tumors., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
294. Positron emission tomography imaging with 89 Zr-labeled anti-CD8 cys-diabody reveals CD8 + cell infiltration during oncolytic virus therapy in a glioma murine model.
- Author
-
Kasten BB, Houson HA, Coleman JM, Leavenworth JW, Markert JM, Wu AM, Salazar F, Tavaré R, Massicano AVF, Gillespie GY, Lapi SE, Warram JM, and Sorace AG
- Subjects
- Animals, CD8 Antigens antagonists & inhibitors, CD8 Antigens isolation & purification, CD8-Positive T-Lymphocytes virology, Cell Line, Tumor, Disease Models, Animal, Glioma diagnostic imaging, Glioma immunology, Glioma virology, Humans, Mice, Radioisotopes pharmacology, Simplexvirus genetics, Tomography, X-Ray Computed, Zirconium pharmacology, CD8 Antigens immunology, CD8-Positive T-Lymphocytes immunology, Glioma therapy, Oncolytic Virotherapy methods
- Abstract
Determination of treatment response to immunotherapy in glioblastoma multiforme (GBM) is a process which can take months. Detection of CD8
+ T cell recruitment to the tumor with a noninvasive imaging modality such as positron emission tomography (PET) may allow for tumor characterization and early evaluation of therapeutic response to immunotherapy. In this study, we utilized89 Zr-labeled anti-CD8 cys-diabody-PET to provide proof-of-concept to detect CD8+ T cell immune response to oncolytic herpes simplex virus (oHSV) M002 immunotherapy in a syngeneic GBM model. Immunocompetent mice (n = 16) were implanted intracranially with GSC005 GBM tumors, and treated with intratumoral injection of oHSV M002 or saline control. An additional non-tumor bearing cohort (n = 4) receiving oHSV M002 treatment was also evaluated. Mice were injected with89 Zr-labeled anti-CD8 cys-diabody seven days post oHSV administration and imaged with a preclinical PET scanner. Standardized uptake value (SUV) was quantified. Ex vivo tissue analyses included autoradiography and immunohistochemistry. PET imaging showed significantly higher SUV in tumors which had been treated with M002 compared to those without M002 treatment (p = 0.0207) and the non-tumor bearing M002 treated group (p = 0.0021). Accumulation in target areas, especially the spleen, was significantly reduced by blocking with the non-labeled diabody (p < 0.001). Radioactive probe accumulation in brains was consistent with CD8+ cell trafficking patterns after oHSV treatment. This PET imaging strategy could aid in distinguishing responders from non-responders during immunotherapy of GBM., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
295. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
- Author
-
Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I, Kachurak K, Nan L, Kang KD, Totsch S, Schlappi C, Martin AM, Pastakia D, McNall-Knapp R, Farouk Sait S, Khakoo Y, Karajannis MA, Woodling K, Palmer JD, Osorio DS, Leonard J, Abdelbaki MS, Madan-Swain A, Atkinson TP, Whitley RJ, Fiveash JB, Markert JM, and Gillespie GY
- Subjects
- Adolescent, Brain Neoplasms diagnostic imaging, Brain Neoplasms pathology, Brain Neoplasms radiotherapy, Child, Child, Preschool, Combined Modality Therapy, Female, Glioma diagnostic imaging, Glioma pathology, Glioma radiotherapy, Humans, Kaplan-Meier Estimate, Killer Cells, Natural, Leukocyte Count, Male, T-Lymphocytes, Brain Neoplasms therapy, Glioma therapy, Oncolytic Virotherapy adverse effects
- Abstract
Background: Outcomes in children and adolescents with recurrent or progressive high-grade glioma are poor, with a historical median overall survival of 5.6 months. Pediatric high-grade gliomas are largely immunologically silent or "cold," with few tumor-infiltrating lymphocytes. Preclinically, pediatric brain tumors are highly sensitive to oncolytic virotherapy with genetically engineered herpes simplex virus type 1 (HSV-1) G207, which lacks genes essential for replication in normal brain tissue., Methods: We conducted a phase 1 trial of G207, which used a 3+3 design with four dose cohorts of children and adolescents with biopsy-confirmed recurrent or progressive supratentorial brain tumors. Patients underwent stereotactic placement of up to four intratumoral catheters. The following day, they received G207 (10
7 or 108 plaque-forming units) by controlled-rate infusion over a period of 6 hours. Cohorts 3 and 4 received radiation (5 Gy) to the gross tumor volume within 24 hours after G207 administration. Viral shedding from saliva, conjunctiva, and blood was assessed by culture and polymerase-chain-reaction assay. Matched pre- and post-treatment tissue samples were examined for tumor-infiltrating lymphocytes by immunohistologic analysis., Results: Twelve patients 7 to 18 years of age with high-grade glioma received G207. No dose-limiting toxic effects or serious adverse events were attributed to G207 by the investigators. Twenty grade 1 adverse events were possibly related to G207. No virus shedding was detected. Radiographic, neuropathological, or clinical responses were seen in 11 patients. The median overall survival was 12.2 months (95% confidence interval, 8.0 to 16.4); as of June 5, 2020, a total of 4 of 11 patients were still alive 18 months after G207 treatment. G207 markedly increased the number of tumor-infiltrating lymphocytes., Conclusions: Intratumoral G207 alone and with radiation had an acceptable adverse-event profile with evidence of responses in patients with recurrent or progressive pediatric high-grade glioma. G207 converted immunologically "cold" tumors to "hot." (Supported by the Food and Drug Administration and others; ClinicalTrials.gov number, NCT02457845.)., (Copyright © 2021 Massachusetts Medical Society.)- Published
- 2021
- Full Text
- View/download PDF
296. N-cadherin upregulation mediates adaptive radioresistance in glioblastoma.
- Author
-
Osuka S, Zhu D, Zhang Z, Li C, Stackhouse CT, Sampetrean O, Olson JJ, Gillespie GY, Saya H, Willey CD, and Van Meir EG
- Subjects
- Adaptation, Physiological, Animals, Antigens, CD genetics, Apoptosis, Brain Neoplasms pathology, Cadherins antagonists & inhibitors, Cadherins genetics, Cell Adhesion, Cell Line, Tumor, Cell Proliferation, Clusterin antagonists & inhibitors, Clusterin genetics, Clusterin metabolism, Female, Gene Knockout Techniques, Glioblastoma pathology, Humans, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Nude, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells pathology, Neoplastic Stem Cells radiation effects, Radiation Tolerance genetics, Up-Regulation, Wnt Signaling Pathway, Xenograft Model Antitumor Assays, Antigens, CD metabolism, Brain Neoplasms metabolism, Brain Neoplasms radiotherapy, Cadherins metabolism, Glioblastoma metabolism, Glioblastoma radiotherapy, Radiation Tolerance physiology
- Abstract
Glioblastoma (GBM) is composed of heterogeneous tumor cell populations, including those with stem cell properties, termed glioma stem cells (GSCs). GSCs are innately less radiation sensitive than the tumor bulk and are believed to drive GBM formation and recurrence after repeated irradiation. However, it is unclear how GSCs adapt to escape the toxicity of repeated irradiation used in clinical practice. To identify important mediators of adaptive radioresistance in GBM, we generated radioresistant human and mouse GSCs by exposing them to repeat cycles of irradiation. Surviving subpopulations acquired strong radioresistance in vivo, which was accompanied by a reduction in cell proliferation and an increase in cell-cell adhesion and N-cadherin expression. Increasing N-cadherin expression rendered parental GSCs radioresistant, reduced their proliferation, and increased their stemness and intercellular adhesive properties. Conversely, radioresistant GSCs lost their acquired phenotypes upon CRISPR/Cas9-mediated knockout of N-cadherin. Mechanistically, elevated N-cadherin expression resulted in the accumulation of β-catenin at the cell surface, which suppressed Wnt/β-catenin proliferative signaling, reduced neural differentiation, and protected against apoptosis through Clusterin secretion. N-cadherin upregulation was induced by radiation-induced IGF1 secretion, and the radiation resistance phenotype could be reverted with picropodophyllin, a clinically applicable blood-brain-barrier permeable IGF1 receptor inhibitor, supporting clinical translation.
- Published
- 2021
- Full Text
- View/download PDF
297. Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.
- Author
-
Omar NB, Bentley RT, Crossman DK, Foote JB, Koehler JW, Markert JM, Platt SR, Rissi DR, Shores A, Sorjonen D, Yanke AB, Gillespie GY, and Chambers MR
- Subjects
- Animals, Dogs, Humans, Interleukin-12, Brain Neoplasms therapy, Glioma therapy, Herpesvirus 1, Human, Oncolytic Virotherapy, Oncolytic Viruses genetics
- Abstract
Objective: The diagnosis of glioma remains disheartening in the clinical realm. While a multitude of studies and trials have shown promise, improvements in overall survival have been disappointing. Modeling these tumors in the laboratory setting has become increasingly challenging, given their complex in situ behavior and interactions for therapeutic evasion. Dogs, particularly brachycephalic breeds, are known to spontaneously develop gliomas that resemble human gliomas both clinically and pathophysiologically, making canines with sporadic tumors promising candidates for study. Typically, survival among these dogs is approximately 2 months with palliation alone., Methods: The authors have completed the first stage of a unique phase I dose-escalating canine clinical trial in which the safety and tolerability of M032, a nonneurovirulent oncolytic herpes simplex virus-1 vector genetically engineered to express interleukin-12, are being studied in pet dogs with gliomas undergoing maximum safe tumor resection and inoculation of the cavity with the viral infusate., Results: Twenty-five canine patients were enrolled between January 2018 and August 2020. One patient was electively withdrawn from the trial by its owner, and 3 did not receive the virus. For the 21 dogs that remained, 13 had high-grade gliomas, 5 had low-grade gliomas, and 3 were undetermined. According to histopathological analysis, 62% of the tumors were oligodendrogliomas. At the time of this report, the median overall survival from the date of treatment was 151 days (± 78 days). No significant adverse events attributable to M032 or dose-limiting toxicities have been observed to date., Conclusions: In this largest study of oncolytic viral therapy for canine brain tumors to date, treatment with M032 did not cause harm and the combination of surgery and oncolytic viral therapy may have contributed to prolonged survival in pet dogs with spontaneous gliomas. Forthcoming in-depth radiographic, immunohistochemical, and genetic analyses will afford a more advanced understanding of how this treatment impacts these tumors and the immune system. Our goal is to utilize these findings bitranslationally to inform human studies and refine therapies that will improve outcomes in both humans and pet dogs with gliomas.
- Published
- 2021
- Full Text
- View/download PDF
298. Glioma stem cells and their roles within the hypoxic tumor microenvironment.
- Author
-
Boyd NH, Tran AN, Bernstock JD, Etminan T, Jones AB, Gillespie GY, Friedman GK, and Hjelmeland AB
- Subjects
- Animals, Brain Neoplasms etiology, Glioma etiology, Humans, Brain Neoplasms pathology, Glioma pathology, Hypoxia physiopathology, Neoplastic Stem Cells pathology, Neovascularization, Pathologic pathology, Tumor Microenvironment immunology
- Abstract
Tumor microenvironments are the result of cellular alterations in cancer that support unrestricted growth and proliferation and result in further modifications in cell behavior, which are critical for tumor progression. Angiogenesis and therapeutic resistance are known to be modulated by hypoxia and other tumor microenvironments, such as acidic stress, both of which are core features of the glioblastoma microenvironment. Hypoxia has also been shown to promote a stem-like state in both non-neoplastic and tumor cells. In glial tumors, glioma stem cells (GSCs) are central in tumor growth, angiogenesis, and therapeutic resistance, and further investigation of the interplay between tumor microenvironments and GSCs is critical to the search for better treatment options for glioblastoma. Accordingly, we summarize the impact of hypoxia and acidic stress on GSC signaling and biologic phenotypes, and potential methods to inhibit these pathways., Competing Interests: Competing Interests: Dr. Bernstock has positions/equity in CITC Ltd and Avidea Technologies and is member of the POCKiT Diagnostics Board of Scientific Advisors. Dr. Gillespie has positions/equity in Treovir, LLC and Aettis, Inc. The remaining authors declare that they have no conflict(s) of interest., (© The author(s).)
- Published
- 2021
- Full Text
- View/download PDF
299. A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma.
- Author
-
Eustace NJ, Anderson JC, Warram JM, Widden HN, Pedersen RT, Alrefai H, Patel Z, Hicks PH, Placzek WJ, Gillespie GY, Hjelmeland AB, and Willey CD
- Subjects
- Animals, Astrocytes, Blood-Brain Barrier cytology, Blood-Brain Barrier metabolism, Brain Neoplasms pathology, Caspases metabolism, Cell Line, Tumor, Cell Membrane Permeability, Drug Resistance, Neoplasm drug effects, Glioblastoma pathology, Humans, Mice, Peptide Fragments genetics, Peptide Fragments therapeutic use, Protein Domains genetics, Signal Transduction drug effects, Tissue Distribution, Xenograft Model Antitumor Assays, Apoptosis drug effects, Brain Neoplasms drug therapy, Glioblastoma drug therapy, Myristoylated Alanine-Rich C Kinase Substrate genetics, Peptide Fragments pharmacology
- Abstract
Glioblastoma (GBM) is an aggressive malignancy with limited effectiveness of standard of care therapies including surgery, radiation, and temozolomide chemotherapy necessitating novel therapeutics. Unfortunately, GBMs also harbor several signaling alterations that protect them from traditional therapies that rely on apoptotic programmed cell death. Because almost all GBM tumors have dysregulated phosphoinositide signaling as part of that process, we hypothesized that peptide mimetics derived from the phospholipid binding domain of Myristoylated alanine-rich C-kinase substrate (MARCKS) could serve as a novel GBM therapeutic. Using molecularly classified patient-derived xenograft (PDX) lines, cultured in stem-cell conditions, we demonstrate that cell permeable MARCKS effector domain (ED) peptides potently target all GBM molecular classes while sparing normal human astrocytes. Cell death mechanistic testing revealed that these peptides produce rapid cytotoxicity in GBM that overcomes caspase inhibition. Moreover, we identify a GBM-selective cytolytic death mechanism involving plasma membrane targeting and intracellular calcium accumulation. Despite limited relative partitioning to the brain, tail-vein peptide injection revealed tumor targeting in intracranially implanted GBM PDX. These results indicate that MARCKS ED peptide therapeutics may overcome traditional GBM resistance mechanisms, supporting further development of similar agents.
- Published
- 2020
- Full Text
- View/download PDF
300. The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas.
- Author
-
Chambers MR, Bentley RT, Crossman DK, Foote JB, Koehler JW, Markert JM, Omar NB, Platt SR, Self DM, Shores A, Sorjonen DC, Waters AM, Yanke AB, and Gillespie GY
- Abstract
As the most common and deadly of primary brain tumors, malignant gliomas have earned their place within one of the most multifaceted and heavily-funded realms of medical research. Numerous avenues of pre-clinical investigation continue to provide valuable insight, but modeling the complex evolution and behavior of these tumors within a host under simulated circumstances may pose challenges to extrapolation of data. Remarkably, certain breeds of pet dogs spontaneously and sporadically develop high grade gliomas that follow similar incidence, treatment, and outcome patterns as their human glioma counterparts. The most malignant of these tumors have been refractory to limited treatment options despite aggressive treatment; outcomes are dismal with median survivals of just over 1 year in humans and 2 months in dogs. Novel treatments are greatly needed and combination therapies appear to hold promise. This clinical protocol, a dose-escalating phase I study in dogs with sporadic malignant glioma, represents a first in comparative oncology and combination immunotherapy. The trial will evaluate M032, an Interleukin-12 expressing Herpes Simplex virus, alone and combined with a checkpoint inhibitor, Indoximod. Extensive pre-clinical work has demonstrated safety of intracranial M032 administration in mice and non-human primates. M032 is currently being tested in humans with high-grade malignant gliomas. Thus, in a novel fashion, both canine and human trials will proceed concurrently allowing a direct "head-to-head" comparison of safety and efficacy. We expect this viral oncolytic therapy to be as safe as it is in human patients and M032 to (a) infect and kill glioma cells, producing a virus and tumor cell antigen-rich debris field; (b) provide an adjuvant effect due to liberation of viral DNA, which is rich in unmethylated CpG sequences that "toggle" TLR-9 receptors; and (c) express IL-12 locally, stimulating induction of TH1 lymphocytes. The resultant immune-mediated anti-viral responses should, through cross-epitope spreading, translate into a strong response to tumor antigens. The ability to compare human and dog responses in real time affords the most stringent test of suitability of the dog as an informative model of human brain tumors. Subsequent studies will allow canine trials to properly inform the design of human trials., (Copyright © 2020 Chambers, Bentley, Crossman, Foote, Koehler, Markert, Omar, Platt, Self, Shores, Sorjonen, Waters, Yanke and Gillespie.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.